Limits...
2H,3H-decafluoropentane-based nanodroplets: new perspectives for oxygen delivery to hypoxic cutaneous tissues.

Prato M, Magnetto C, Jose J, Khadjavi A, Cavallo F, Quaglino E, Panariti A, Rivolta I, Benintende E, Varetto G, Argenziano M, Troia A, Cavalli R, Guiot C - PLoS ONE (2015)

Bottom Line: Dextran-shelled OLNDs, available either in liquid or gel formulations, display spherical morphology, ~600 nm diameters, anionic charge, good oxygen carrying capacity, and no toxic effects on human keratinocytes after cell internalization.In vivo, OLNDs effectively enhance oxy-hemoglobin levels, as emerged from investigation by photoacoustic imaging.Taken together, these data suggest that US-activated, DFP-based OLNDs might be innovative, suitable and cost-effective devices to topically treat hypoxia-associated pathologies of the cutaneous tissues.

View Article: PubMed Central - PubMed

Affiliation: Dipartimento di Neuroscienze, Università di Torino, Torino, Italy.

ABSTRACT
Perfluoropentane (PFP)-based oxygen-loaded nanobubbles (OLNBs) were previously proposed as adjuvant therapeutic tools for pathologies of different etiology sharing hypoxia as a common feature, including cancer, infection, and autoimmunity. Here we introduce a new platform of oxygen nanocarriers, based on 2H,3H-decafluoropentane (DFP) as core fluorocarbon. These new nanocarriers have been named oxygen-loaded nanodroplets (OLNDs) since DFP is liquid at body temperature, unlike gaseous PFP. Dextran-shelled OLNDs, available either in liquid or gel formulations, display spherical morphology, ~600 nm diameters, anionic charge, good oxygen carrying capacity, and no toxic effects on human keratinocytes after cell internalization. In vitro OLNDs result more effective in releasing oxygen to hypoxic environments than former OLNBs, as demonstrated by analysis through oxymetry. In vivo, OLNDs effectively enhance oxy-hemoglobin levels, as emerged from investigation by photoacoustic imaging. Interestingly, ultrasound (US) treatment further improves transdermal oxygen release from OLNDs. Taken together, these data suggest that US-activated, DFP-based OLNDs might be innovative, suitable and cost-effective devices to topically treat hypoxia-associated pathologies of the cutaneous tissues.

No MeSH data available.


Related in: MedlinePlus

Topical treatment with OLND gel formulation effectively enhances oxy-Hb levels in vivo.The shaved hind limbs of nine anesthetized mice were monitored by photoacoustics for oxy-Hb and deoxy-Hb levels before (0 min, upper row), during (0–10 min, central row) and after (10 min, lower row) topical treatment with OSS (first column), OLND (second column) and OFND (third column) gel formulations. White/red pixels: oxy-Hb; blue pixels: deoxy-Hb. Data are shown as representative images from three independent experiments (three mice per experiment) with similar results.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4362938&req=5

pone.0119769.g006: Topical treatment with OLND gel formulation effectively enhances oxy-Hb levels in vivo.The shaved hind limbs of nine anesthetized mice were monitored by photoacoustics for oxy-Hb and deoxy-Hb levels before (0 min, upper row), during (0–10 min, central row) and after (10 min, lower row) topical treatment with OSS (first column), OLND (second column) and OFND (third column) gel formulations. White/red pixels: oxy-Hb; blue pixels: deoxy-Hb. Data are shown as representative images from three independent experiments (three mice per experiment) with similar results.

Mentions: The skin oxygenation of the shaved hind limbs of nine anesthetized mice topically treated with OLND, OFND or OSS gel formulations was monitored by visualizing the subcutaneous levels of oxy-Hb and deoxy-Hb through photoacoustic imaging before, during and after the treatment (t = 10 min). As shown in Fig. 6, oxy-Hb levels significantly increased for the entire observational period in the animals treated with OLNDs. As expected, OSS induced a high but only transient peak in oxy-Hb, whereas OFNDs did not affect oxy-/deoxy-Hb balances at all.


2H,3H-decafluoropentane-based nanodroplets: new perspectives for oxygen delivery to hypoxic cutaneous tissues.

Prato M, Magnetto C, Jose J, Khadjavi A, Cavallo F, Quaglino E, Panariti A, Rivolta I, Benintende E, Varetto G, Argenziano M, Troia A, Cavalli R, Guiot C - PLoS ONE (2015)

Topical treatment with OLND gel formulation effectively enhances oxy-Hb levels in vivo.The shaved hind limbs of nine anesthetized mice were monitored by photoacoustics for oxy-Hb and deoxy-Hb levels before (0 min, upper row), during (0–10 min, central row) and after (10 min, lower row) topical treatment with OSS (first column), OLND (second column) and OFND (third column) gel formulations. White/red pixels: oxy-Hb; blue pixels: deoxy-Hb. Data are shown as representative images from three independent experiments (three mice per experiment) with similar results.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4362938&req=5

pone.0119769.g006: Topical treatment with OLND gel formulation effectively enhances oxy-Hb levels in vivo.The shaved hind limbs of nine anesthetized mice were monitored by photoacoustics for oxy-Hb and deoxy-Hb levels before (0 min, upper row), during (0–10 min, central row) and after (10 min, lower row) topical treatment with OSS (first column), OLND (second column) and OFND (third column) gel formulations. White/red pixels: oxy-Hb; blue pixels: deoxy-Hb. Data are shown as representative images from three independent experiments (three mice per experiment) with similar results.
Mentions: The skin oxygenation of the shaved hind limbs of nine anesthetized mice topically treated with OLND, OFND or OSS gel formulations was monitored by visualizing the subcutaneous levels of oxy-Hb and deoxy-Hb through photoacoustic imaging before, during and after the treatment (t = 10 min). As shown in Fig. 6, oxy-Hb levels significantly increased for the entire observational period in the animals treated with OLNDs. As expected, OSS induced a high but only transient peak in oxy-Hb, whereas OFNDs did not affect oxy-/deoxy-Hb balances at all.

Bottom Line: Dextran-shelled OLNDs, available either in liquid or gel formulations, display spherical morphology, ~600 nm diameters, anionic charge, good oxygen carrying capacity, and no toxic effects on human keratinocytes after cell internalization.In vivo, OLNDs effectively enhance oxy-hemoglobin levels, as emerged from investigation by photoacoustic imaging.Taken together, these data suggest that US-activated, DFP-based OLNDs might be innovative, suitable and cost-effective devices to topically treat hypoxia-associated pathologies of the cutaneous tissues.

View Article: PubMed Central - PubMed

Affiliation: Dipartimento di Neuroscienze, Università di Torino, Torino, Italy.

ABSTRACT
Perfluoropentane (PFP)-based oxygen-loaded nanobubbles (OLNBs) were previously proposed as adjuvant therapeutic tools for pathologies of different etiology sharing hypoxia as a common feature, including cancer, infection, and autoimmunity. Here we introduce a new platform of oxygen nanocarriers, based on 2H,3H-decafluoropentane (DFP) as core fluorocarbon. These new nanocarriers have been named oxygen-loaded nanodroplets (OLNDs) since DFP is liquid at body temperature, unlike gaseous PFP. Dextran-shelled OLNDs, available either in liquid or gel formulations, display spherical morphology, ~600 nm diameters, anionic charge, good oxygen carrying capacity, and no toxic effects on human keratinocytes after cell internalization. In vitro OLNDs result more effective in releasing oxygen to hypoxic environments than former OLNBs, as demonstrated by analysis through oxymetry. In vivo, OLNDs effectively enhance oxy-hemoglobin levels, as emerged from investigation by photoacoustic imaging. Interestingly, ultrasound (US) treatment further improves transdermal oxygen release from OLNDs. Taken together, these data suggest that US-activated, DFP-based OLNDs might be innovative, suitable and cost-effective devices to topically treat hypoxia-associated pathologies of the cutaneous tissues.

No MeSH data available.


Related in: MedlinePlus